Lexeo Therapeutics
LXEO
NASDAQ
IPO2023
about LXEO
Lexeo Therapeutics is a clinical-stage biotechnology company focused on advancing innovative gene-editing therapies using its proprietary Precision Genome Editing platform to address a broad range of diseases.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $9.38 | $9.60 | $6.90 | $769.29M | 5.17M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$0.33 | n/a | n/a | 0% | 0% | 0% |